Unlock instant, AI-driven research and patent intelligence for your innovation.

Alpha-cinnamide compounds and compositions as hdac8 inhibitors

Active Publication Date: 2016-09-15
VALO HEALTH INC
View PDF1 Cites 17 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention is about a new compound that can treat, prevent, inhibit, or remove a disease or disorder in a patient by targeting a specific protein called HDAC8. The compound can be administered to the patient in a therapeutically effective amount. The technical effect of this invention is to provide a new treatment option for diseases or disorders associated with the inhibition of HDAC8, which can help improve patient outcomes and reduce the burden of disease.

Problems solved by technology

While the potential for HDAC inhibitors as treatment for non-oncology indications has been recognized, one has yet to be approved.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Alpha-cinnamide compounds and compositions as hdac8 inhibitors
  • Alpha-cinnamide compounds and compositions as hdac8 inhibitors
  • Alpha-cinnamide compounds and compositions as hdac8 inhibitors

Examples

Experimental program
Comparison scheme
Effect test

example 1

Intermediate Int-1: (E)-methyl 3-(2-aminophenyl)acrylate

[0853]

[0854]Step-1: (E)-methyl 3-(2-aminophenyl)acrylate. Into a 1-L 3-necked round-bottom flask, was placed 2-bromoaniline (55 g, 319.72 mmol, 1.00 equiv), N,N-dimethylformamide (500 mL), methyl prop-2-enoate (275 g, 3.19 mol, 10.00 equiv), TEA (97 g, 958.59 mmol, 3.00 equiv), Pd(dppf)Cl2.CH2Cl2 (13 g, 0.05 equiv) and water (0.5 mL). The resulting solution was stirred overnight at 110° C. The reaction mixture was then cooled to room temperature and poured into 2 L of water, extracted with 3×800 mL of ethyl acetate, washed with 1000 mL of brine, dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was applied onto a silica gel column with ethyl acetate / petroleum ether (1:4). The collected fraction was concentrated under vacuum to give (E)-methyl 3-(2-aminophenyl)acrylate (17.6 g, 31%) as a green solid. 1H-NMR (DMSO, 400 MHz) δ(ppm): 7.90 (d, J=16 Hz, 1H), 7.45 (d, J=8 Hz, 1H), 7.10-7.06 (m, 1H), 6.70 (...

example 2

Intermediate Int-2: (E)-methyl 3-(2-bromophenyl)acrylate

[0855]

Step-1: (E)-methyl 3-(2-bromophenyl)acrylate

[0856]Into a 250-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed methyl 2-(dimethoxyphosphoryl)acetate (12 g, 65.89 mmol, 1.20 equiv), tetrahydrofuran (100 mL). This was followed by the addition of sodium hydride (60% in oil, 2.4 g, 60.00 mmol, 1.11 equiv) at 0° C. The mixture was stirred for 30 min at 0. Then 2-bromobenzaldehyde (10 g, 54.05 mmol, 1.00 equiv) was added at 0° C. The resulting solution was stirred for additional 10 min at 0° C. The reaction mixture was then poured into 500 mL of water, extracted with 500 mL of ethyl acetate, washed with 50 mL of brine, dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was applied onto a silica gel column with ethyl acetate / petroleum ether (1:5). The collected fraction was concentrated under vacuum to give (E)-methyl 3-(2-bromophenyl)acrylate (9 g, 69%) as y...

example 3

Intermediate Int-3: (E)-tert-butyl 3-(2-bromophenyl)acrylate

[0857]

Step-1: Synthesis of (E)-tert-butyl 3-(2-bromophenyl)acrylate

[0858]Into a 250-mL 3-necked round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed a solution of sodium hydride (60%, 1.32 g, 55.00 mmol, 1.10 equiv) in tetrahydrofuran (100 mL). This was followed by the addition of a solution of tert-butyl 2-(diethoxyphosphoryl)acetate (9.1 g, 36.08 mmol, 1.20 equiv) in tetrahydrofuran (10 mL) dropwise with stirring at 0° C. The resulting solution was stirred for 30 min at 0° C. To this was added a solution of 2-bromobenzaldehyde (5.55 g, 30.00 mmol, 1.00 equiv) in tetrahydrofuran (10 mL) dropwise with stirring at 0° C. The resulting solution was allowed to react overnight at room temperature. The reaction mixture was poured into 250 mL of water, extracted with 200 mL of ethyl acetate, washed with 500 mL of brine, dried over anhydrous sodium sulfate and concentrated under vacuum. The resi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Volumeaaaaaaaaaa
Volumeaaaaaaaaaa
Volumeaaaaaaaaaa
Login to View More

Abstract

The present invention relates to inhibitors of histone deacetylases, in particular HDAC8, that are useful for the treatment of cancer and other diseases and disorders, as well as the synthesis and applications of said inhibitors.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application claims the benefit of priority of U.S. Provisional Application No. 62 / 132,895, filed Mar. 13, 2015, U.S. Provisional Application No. 62 / 184,335, filed Jun. 25, 2015 and U.S. Provisional Application No. 62 / 270,371, filed Dec. 21, 2015, all of which are incorporated herein by reference.FIELD OF THE INVENTION[0002]The subject of this invention is applicable to the treatment of cancer, neurodegeneration, and inflammation. Furthermore, the inhibition of histone deacetylases has also been associated with other diseases including autoimmune, infectious, metabolic, or cardiovascular diseases or disorders. The present invention relates to compounds and compositions for inhibition of histone deacetylases, in particular HDAC8, as well as their synthesis and applications.BACKGROUND OF THE INVENTION[0003]Histone deacetylases (HDACs) are enzymes that regulate epigenetics by removal of acetyl groups from the lysine residues of proteins,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07C259/06C07D221/20A61K31/438A61K31/277C07D209/44A61K31/4035C07D295/155A61K31/451C07D471/10A61K31/435C07D487/10A61K31/407C07D495/10A61K31/397C07D235/14A61K31/4184C07C275/38C07D233/68A61K31/417C07D213/56A61K31/44C07D241/08A61K31/495C07D417/04A61K31/4439A61K31/5377C07D471/04A61K31/185
CPCC07C259/06A61K31/185C07D221/20A61K31/438A61K31/277C07D209/44A61K31/4035C07D295/155A61K31/451C07D471/10A61K31/435C07D487/10A61K31/407C07D495/10A61K31/397C07D235/14A61K31/4184C07C275/38C07D233/68A61K31/417C07D213/56A61K31/44C07D241/08A61K31/495C07D417/04A61K31/4439A61K31/5377C07D471/04C07D401/14C07D213/75C07D213/81C07D215/12C07D317/68C07D231/14C07D231/18C07D233/36C07D233/38C07D333/70C07D401/04C07D401/12C07D235/30C07D239/20C07D239/22C07D405/12C07D409/04C07D409/12C07D241/12C07D417/12C07D249/18C07D257/04C07D261/18C07D487/04C07D487/08C07D491/10C07D207/10C07D493/08C07D207/267C07D498/04C07D209/08C07D277/56C07D209/42C07D209/46C07D513/10C07D211/16C07D211/58C07D295/192C07D213/65C07D307/68A61P1/00A61P1/04A61P1/16A61P11/02A61P11/06A61P13/02A61P17/00A61P17/02A61P17/06A61P19/02A61P19/04A61P21/04A61P25/00A61P25/08A61P25/14A61P25/16A61P25/28A61P27/14A61P27/16A61P29/00A61P3/00A61P3/04A61P31/00A61P31/04A61P31/12A61P31/14A61P31/16A61P31/20A61P31/22A61P33/00A61P33/06A61P35/00A61P35/02A61P37/06A61P37/08A61P43/00A61P7/00A61P7/06A61P9/00A61P9/04A61P9/10A61P9/14A61P3/10Y02A50/30
Inventor BAIR, KENNETH WBARCZAK, NICHOLASHAN, BINGSONGLANCIA, JR., DAVID R.LIU, CUIXIANMARTIN, MATTHEW WNG, PUI YEERUDNITSKAYA, ALEKSANDRATHOMASON, JENNIFER RZABLOCKI, MARY MARGARETZHENG, XIAOZHANG
Owner VALO HEALTH INC